StockData
Vertex Pharmaceuticals Inc logo

Vertex Pharmaceuticals Inc

VRTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026Score 15/3037% above fair value
$553.15−5.73 (-1.03%)

Close on Nov 2, 2026Market cap $140.20BP/E 32.2Yield –

Vertex Pharmaceuticals Other accrued expenses by Year

Other accrued expenses ($M) ($M)

Vertex Pharmaceuticals Other accrued expenses: $46.7M in FY2025, down 32.6% from a year earlier.

Latest, FY2025
46.7
Period ended Dec 31, 2025
Change on a year earlier
-32.6%
69.3 in FY2024
History
11 years
Since FY2015
Sources
10
Documents cited below

Where the FY2025 figure comes from

Source: Form 10-K (filed 2026-02-13) ↗

Reported in Form 10-K Note (Accrued Expenses Breakdown).

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedOther accrued expenses ($M) ($M)Year on yearSource
FY2025Dec 31, 202546.7-32.6%Form 10-K (filed 2026-02-13) ↗
FY2024Dec 31, 202469.3+66.6%Form 10-K (filed 2026-02-13) ↗
FY2023Dec 31, 202341.6-1.9%Form 10-K (filed 2025-02-13) ↗
FY2022Dec 31, 202242.4-25.1%Form 10-K (filed 2024-02-15) ↗
FY2021Dec 31, 202156.6+19.4%Form 10-K (filed 2023-02-10) ↗
FY2020Dec 31, 202047.4+20.0%Form 10-K (filed 2022-02-09) ↗
FY2019Dec 31, 201939.5+61.9%Form 10-K (filed 2021-02-11) ↗
FY2018Dec 31, 201824.4-38.4%Form 10-K (filed 2020-02-13) ↗
FY2017Dec 31, 201739.6+48.3%Form 10-K (filed 2019-02-13) ↗
FY2016Dec 31, 201626.7+126.3%Form 10-K (filed 2018-02-15) ↗
FY2015Dec 31, 201511.8–Form 10-K (filed 2017-02-23) ↗

Cite this data

StockData. (2026). Vertex Pharmaceuticals Other accrued expenses ($M), annual FY2015–FY2025 [Data set]. Compiled from Vertex Pharmaceuticals SEC filings and investor materials. https://stockdatahq.com/stocks/vrtx/kpis/accrued-other

See every metric in the Vertex Pharmaceuticals KPI table. Data updated Nov 2, 2026.